Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
• Treatments: Cetuximab; Pemetrexed

Criteria

Inclusion Criteria:

• non-squamous stage III non-small cell lung cancer

• measurable disease (RECIST 1.1)

• ECOG performance status 0-1

• normal organ and marrow function

Exclusion Criteria:

• prior chest radiation therapy

• history of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years.

• Prior therapy with known specific inhibitors of the EGFR.

• history of severe allergic reaction to prior therapy with monoclonal antibodies